Novo Nordisk $NOVO B (-1.36%) shows significant progress in weight loss with CagriSema. The latest results of the REDEFINE 2 study, published on March 10, 2025, are a real gamechanger. In this Phase 3 study, 1,206 participants with overweight or obesity and type 2 diabetes underwent 68 weeks of treatment. The combination of cagrilintide and semaglutide, better known as CagriSema, has been shown to be not only effective but also safe. Compared to subjects receiving a placebo, patients taking CagriSema experienced an impressive 15.7% weight loss. A full 89.7% of participants in the CagriSema group were able to lose at least 5% of their body weight. The side effects were predominantly mild to moderate and even decreased over the course of the study. With the goal of filing for approval for CagriSema in the first quarter of 2026, Novo Nordisk shows that they are ready to set new standards in the treatment of obesity.
In Germany, the alliance is in $ALV (+0.98%) is in exclusive negotiations with Cinven to acquire the insurance specialist Viridium. This strategic decision could be an important step towards expansion for Allianz. With an estimated purchase price of around 3 billion euros, Allianz has prevailed over other interested parties, including Athora. Viridium specializes in the acquisition of life insurance policies and manages impressive assets of over 67 billion euros. Viridium's net profit in 2023 amounted to 342 million euros, which underlines the attractiveness of the company. Interestingly, Cinven acquired Viridium from Lloyds Banking Group in 2013 for around €300 million and has since expanded significantly through strategic acquisitions. In XETRA trading, the Allianz share reacted positively to the news and recorded an increase of 0.41% to 344.60 euros.
Sources:
